Histology
Non-Small Cell Adenocarcinoma
CI-CAN-00003439Explore in graph →
53 active trials127 evidence items
- NCIt
- C27745
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00003439Explore in graph →
Clinical trials
236 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (29)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04692935 | Comparative Genomic Profiling of Lung Adenocarcinoma in Asians and Caucasians: A Propensity Matched Analysis | unknown | — | 450 | Jun WangOTHER | 0 | Jan 5, 2021 | clinicaltrials |
| NCT02276027 | A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 66 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 16, 2020 | clinicaltrials |
| NCT03254004 | Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm | unknown | Phase 2 | 70 | Samsung Medical CenterOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT03896958 | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)(PIONEER) | unknown | — | 1,000 | SpeciCareINDUSTRY | 1 | Dec 4, 2020 | clinicaltrials |
| NCT03361319 | Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma(N3) | withdrawn | Phase 1 / Phase 2 | 0 | Royal Marsden NHS Foundation TrustOTHER | 0 | Nov 24, 2020 | clinicaltrials |
| NCT01958372 | Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer | completed | Phase 1 | 11 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT02616211 | An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors | completed | — | 15 | Mayo ClinicOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT04554875 | Derivation and Validation of a Scoring System to Distinguish Cryptococcosis and Adenocarcinoma in Pulmonary Nodules | unknown | — | 1,000 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Sep 18, 2020 | clinicaltrials |
| NCT00950365 | Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 79 | Albert Einstein College of MedicineOTHER | 1 | Sep 16, 2020 | clinicaltrials |
| NCT01218516 | A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung | completed | Phase 2 | 130 | MorphotekINDUSTRY | 8 | Aug 20, 2020 | clinicaltrials |
| NCT04493827 | Distribution and Prognostic Impact of Oncogenic Drivers in Metastatic Lung Adenocarcinoma : a Retrospective Monocentric Study in Nancy University Hospital Center | completed | — | 114 | Central Hospital, Nancy, FranceOTHER | 1 | Jul 30, 2020 | clinicaltrials |
| NCT04482829 | TCM in the Treatment of Lung Adenocarcinoma | unknown | N/A | 144 | Henan University of Traditional Chinese MedicineOTHER | 0 | Jul 23, 2020 | clinicaltrials |
| NCT02737774 | Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation | unknown | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 1, 2020 | clinicaltrials |
| NCT04086680 | The Detection of EGFR Mutations in Liquid Based Cytology Samples | completed | — | 13 | Royal Cornwall Hospitals TrustOTHER | 1 | Jun 22, 2020 | clinicaltrials |
| NCT00073398 | Vaccine Treatment for Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 54 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT03704870 | Outcomes Following Omission of Daily Routine Chest Radiographs Following Pulmonary Resection | completed | Phase 2 | 50 | University Health Network, TorontoOTHER | 1 | May 1, 2020 | clinicaltrials |
| NCT02134912 | S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib | terminated | Phase 2 | 1 | SWOG Cancer Research NetworkNETWORK | 1 | Feb 20, 2020 | clinicaltrials |
| NCT03059641 | Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China | completed | — | 300 | Geneplus-Beijing Co. Ltd.INDUSTRY | 1 | Feb 5, 2020 | clinicaltrials |
| NCT01707823 | Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer | terminated | Early Phase 1 | 4 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT03544814 | EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression | completed | Phase 2 | 99 | Shanghai Chest HospitalOTHER | 0 | Oct 15, 2019 | clinicaltrials |
| NCT01259089 | Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 38 | Northwestern UniversityOTHER | 1 | Sep 11, 2019 | clinicaltrials |
| NCT02466568 | Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung | withdrawn | Phase 1 / Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Sep 9, 2019 | clinicaltrials |
| NCT00126581 | Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer | completed | Phase 2 | 188 | National Cancer Institute (NCI)NIH | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01362790 | SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | completed | Phase 1 / Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2019 | clinicaltrials |
| NCT03905317 | Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene | unknown | Phase 2 | 66 | Sun Yat-sen UniversityOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT03838588 | The Tracking Molecular Evolution for NSCLC (T-MENC) Study | unknown | — | 200 | Geneplus-Beijing Co. Ltd.INDUSTRY | 1 | Feb 12, 2019 | clinicaltrials |
| NCT02891733 | Retrospective Analysis of the Expression of the Neurotensin Receptor by Metastatic Lung Adenocarcinomas(NTS) | withdrawn | — | 0 | Fondation Hôpital Saint-JosephOTHER | 0 | Feb 4, 2019 | clinicaltrials |
| NCT01578551 | Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. | terminated | Phase 2 | 25 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT01557959 | Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 45 | Wake Forest University Health SciencesOTHER | 1 | Jun 29, 2018 | clinicaltrials |
| NCT00955305 | Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | terminated | Phase 2 | 175 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2018 | clinicaltrials |
| NCT02979821 | Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001) | completed | Phase 2 | 6 | Korean Association for the Study of Targeted TherapyOTHER | 1 | May 24, 2018 | clinicaltrials |
| NCT03486496 | Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation(Geber) | unknown | Phase 2 | 50 | Fujian Cancer HospitalOTHER_GOV | 1 | Apr 3, 2018 | clinicaltrials |
| NCT02093000 | A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma | completed | — | 201 | Hoffmann-La RocheINDUSTRY | 1 | Feb 23, 2018 | clinicaltrials |
| NCT03351842 | Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20% | recruiting | Phase 2 | 460 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 19, 2017 | clinicaltrials |
| NCT03376737 | Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma | unknown | Phase 2 | 120 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 18, 2017 | clinicaltrials |
| NCT02121925 | Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up(ONC003) | terminated | — | 227 | Myriad Genetic Laboratories, Inc.INDUSTRY | 1 | Sep 5, 2017 | clinicaltrials |
| NCT02715102 | Circulating Tumor DNA in Patients at High Risk for Lung Cancer | terminated | — | 39 | Pathway GenomicsINDUSTRY | 1 | Aug 21, 2017 | clinicaltrials |
| NCT02679443 | Vitamin Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy(PEMVITASTART) | completed | N/A | 161 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT01726296 | Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care | completed | N/A | 1,440 | Fox Chase Cancer CenterOTHER | 1 | Apr 6, 2017 | clinicaltrials |
| NCT03090815 | Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma | unknown | — | 100 | The University of Hong KongOTHER | 1 | Mar 27, 2017 | clinicaltrials |
| NCT03071705 | Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma | unknown | N/A | 120 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT02282267 | Blood Detection of EGFR Mutation For Iressa Treatment(Benefit) | unknown | N/A | 188 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 24, 2017 | clinicaltrials |
| NCT01294306 | MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2016 | clinicaltrials |
| NCT02787447 | Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy | unknown | Phase 2 | 46 | First People's Hospital of HangzhouOTHER | 1 | Nov 25, 2016 | clinicaltrials |
| NCT02951897 | Application of Detecting Circulating Tumor Cells in the Accurate Treatment of Early Stage Lung Adenocarcinoma(CTCs detection) | unknown | N/A | 120 | Third Military Medical UniversityOTHER | 1 | Nov 2, 2016 | clinicaltrials |
| NCT02951637 | Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial | unknown | Phase 2 | 300 | Shanghai Chest HospitalOTHER | 0 | Nov 1, 2016 | clinicaltrials |
| NCT02946216 | ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC | unknown | — | 200 | First People's Hospital of HangzhouOTHER | 1 | Oct 27, 2016 | clinicaltrials |
| NCT02898857 | Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma(NOTCH) | unknown | — | 18 | University Hospital, MontpellierOTHER | 1 | Sep 13, 2016 | clinicaltrials |
| NCT02843711 | Molecular Analysis of 150 Lung Adenocarcinoma(LUNG-EST) | unknown | — | 152 | Hospices Civils de LyonOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT02804646 | Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma | unknown | Phase 4 | 100 | Anhui Provincial HospitalOTHER_GOV | 1 | Jun 21, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Jan 5, 2021source: clinicaltrials